undamentalytics Newsletter
Sign in

Inhibrx Biosciences, Inc. balance sheet

At the end of fiscal 2025, Inhibrx Biosciences, Inc. had total assets of $146m, total liabilities of $138m and shareholders' equity of $8.0m. It held $124m in cash against $101m of debt: net cash of $23.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents278153124
Total current assets295160133
Total assets308181146
Accounts payable1196
Total current liabilities564134
Long-term debt2070101
Total debt2070101
Total liabilities26447138
Shareholders' equity441348
Net debt (negative = net cash)−71−153−24
Shares outstanding—14m15m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: DARE vs INBXINBX vs LGVNINBX vs RNAC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inhibrx Biosciences, Inc.